Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium

Conditions:   Adenocarcinoma of the Bladder;   Distal Urethral Cancer;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Proximal Urethral Cancer;   Recurrent Bladder Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Regional Transitional Cell Cancer of the Renal Pelvis and Ureter;   Squamous Cell Carcinoma of the Bladder;   Stage III Bladder Cancer;   Stage IV Bladder Cancer;   Transitional Cell Carcinoma of the Bladder;   Urethral Cancer Associated With Invasive Bladder CancerInterventions:   Drug: sorafenib tosylate;   Other: laboratory biomarker analysisSponsor:   National Cancer Institute (NCI)Terminated - verified December 2012
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials